Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Investing Activities (2016 - 2025)

Coherus Oncology's Cash from Investing Activities history spans 13 years, with the latest figure at -$2.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 423.62% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached $375.1 million, up 62.85%, while the annual FY2025 figure was $375.1 million, 62.85% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$2.8 million at Coherus Oncology, up from -$67.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $462.6 million in Q2 2025 and bottomed at -$285.5 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $8.2 million (2021), against an average of $22.2 million.
  • The largest annual shift saw Cash from Investing Activities crashed 17565.53% in 2021 before it soared 11160.39% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $107.5 million in 2021, then crashed by 220.85% to -$129.9 million in 2022, then soared by 127.1% to $35.2 million in 2023, then tumbled by 101.54% to -$542000.0 in 2024, then plummeted by 423.62% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cash from Investing Activities are -$2.8 million (Q4 2025), -$67.2 million (Q3 2025), and $462.6 million (Q2 2025).